Published online before print March 21, 2005, doi: 10.1161/01.CIR.0000159340.93220.E4
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;111:1487-1491.)
© 2005 American Heart Association, Inc.
Heart Failure |
Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure
From the Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, NY (J.D.S.-B., H.A.S.), and Division of Cardiovascular Medicine, University of Michigan, Ann Arbor (K.D.A.).
Correspondence to Jonathan D. Sackner-Bernstein, MD, FACC, Clinical Scholars Program, Division of Cardiology, Cohen 1, North Shore University Hospital, 300 Community Dr, Manhasset, NY 11030. E-mail jonathansb{at}yahoo.com
Received August 13, 2004; revision received November 26, 2004; accepted January 11, 2005.
Background— Renal function is an important prognostic factor for patients with acutely decompensated heart failure (ADHF). We investigated the renal effects of nesiritide as treatment for ADHF.
Methods and Results— Randomized clinical trials comparing nesiritide with either placebo or active control for ADHF were identified by electronic and manual searches and thorough review of US Food and Drug Administration files available via the website. Worsening renal function was defined as an increase in serum creatinine >0.5 mg/dL. Relative risk across all studies was determined by meta-analysis with Mantel-Haenszel fixed-effects models (RRMH). Risk of dialysis and medical intervention for worsening renal function were compared between therapies. Frequency of worsening renal function was determined from 5 randomized studies that included 1269 patients. Use of Food and Drug Administration–approved doses of nesiritide (
0.03 µg · kg–1 · min–1) significantly increased the risk of worsening renal function compared with non–inotrope-based control (RRMH, 1.52; 95% CI, 1.16 to 2.00; P=0.003) or any control therapy, including non–inotrope- and inotrope-based therapies (RRMH, 1.54; 95% CI, 1.19 to 1.98; P=0.001). Even low-dose nesiritide (0.015 µg · kg–1 · min–1) significantly increased risk (P=0.012 and P=0.006 compared with non–inotrope- and inotrope-based controls, respectively), as did nesiritide administered at any dose up to 0.06 µg · kg–1 · min–1 (P=0.002 and P=0.001, respectively). There was no difference in the need for dialysis between therapies.
Conclusions— Nesiritide significantly increases the risk of worsening renal function in patients with ADHF. Whether worsening renal function reflects hemodynamic effect or renal injury is unknown, but the prognostic importance of worsening renal function suggests the need for further investigation in appropriately powered clinical trials.
Key Words: heart failure • kidney • meta-analysis • natriuretic peptides • pharmacology
Related Articles:
Circulation 2005 111: 1455.
Circulation 2005 111: 1459-1461.
This article has been cited by other articles:
 |
|
 |
|
  W. Mullens, Z. Abrahams, G. S. Francis, H. N. Skouri, R. C. Starling, J. B. Young, D. O. Taylor, and W.H. W. Tang Sodium nitroprusside for advanced low-output heart failure. J. Am. Coll. Cardiol., July 15, 2008; 52(3): 200 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Yancy Vasodilator therapy for decompensated heart failure. J. Am. Coll. Cardiol., July 15, 2008; 52(3): 208 - 210. [Full Text] [PDF]
|
|
|
|
|
|
O. Lisy, B. K. Huntley, D. J. McCormick, P. A. Kurlansky, and J. C. Burnett Jr Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide: CD-NP. J. Am. Coll. Cardiol., July 1, 2008; 52(1): 60 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mrkobrada, H. Thiessen-Philbrook, R. B. Haynes, A. V. Iansavichus, F. Rehman, and A. X. Garg Need for Quality Improvement in Renal Systematic Reviews Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1102 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Burnett Jr and J. Korinek The Tumultuous Journey of Nesiritide: Past, Present, and Future Circ Heart Fail, May 1, 2008; 1(1): 6 - 8. [Full Text] [PDF]
|
|
|
|
|
|
C. W. Yancy, H. Krum, B. M. Massie, M. A. Silver, L. W. Stevenson, M. Cheng, S. S. Kim, R. Evans, and for the FUSION II Investigators Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure: Results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial Circ Heart Fail, May 1, 2008; 1(1): 9 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R J Hillock, C M Frampton, T G Yandle, R W Troughton, J G Lainchbury, and A M Richards B-type natriuretic peptide infusions in acute myocardial infarction Heart, May 1, 2008; 94(5): 617 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Pang, J. G.F. Cleland, J. R. Teerlink, S. P. Collins, C. J. Lindsell, G. Sopko, W. F. Peacock, G. C. Fonarow, A. Z. Aldeen, J. D. Kirk, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach Eur. Heart J., March 2, 2008; 29(6): 816 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Herget-Rosenthal, F. Saner, and L. S. Chawla Approach to Hemodynamic Shock and Vasopressors Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 546 - 553. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J DiDomenico, A. Perez, H. M Schumann, D. R Fontana, G. T Kondos, and G. T Schumock Impact of Treatment Guidelines on Clinical and Economic Outcomes of Acute Decompensated Heart Failure Ann. Pharmacother., March 1, 2008; 42(3): 327 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kazory and E. A. Ross Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective Circulation, February 19, 2008; 117(7): 975 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Mullens, Z. Abrahams, H. N. Skouri, G. S. Francis, D. O. Taylor, R. C. Starling, E. Paganini, and W.H. W. Tang Elevated Intra-Abdominal Pressure in Acute Decompensated Heart Failure: A Potential Contributor to Worsening Renal Function? J. Am. Coll. Cardiol., January 22, 2008; 51(3): 300 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Iglesias, L. DePalma, D. Hom, M. Antoniotti, S. Ayoub, and J. S. Levine Predictors of mortality in adult patients with congestive heart failure receiving nesiritide Retrospective analysis showing a potential adverse interaction between neseritide and acute renal dysfunction Nephrol. Dial. Transplant., January 1, 2008; 23(1): 144 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. V. McMurray, J. R. Teerlink, G. Cotter, R. C. Bourge, J. G. F. Cleland, G. Jondeau, H. Krum, M. Metra, C. M. O'Connor, J. D. Parker, et al. Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure: The VERITAS Randomized Controlled Trials JAMA, November 7, 2007; 298(17): 2009 - 2019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Silver and C. W. Yancy Using Homeostatic Peptides in Decompensated Heart Failure: A Reasonable Paradigm But a Flawed Practice? J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1841 - 1843. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Witteles, D. Kao, D. Christopherson, K. Matsuda, R. H. Vagelos, D. Schreiber, and M. B. Fowler Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1835 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Arora, K. Clarke, V. Srinivasan, and A. Gradman Effect of nesiritide on renal function in patients admitted for decompensated heart failure QJM, November 1, 2007; 100(11): 699 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. L. Martin, T. Supaporn, H. H. Chen, S. M. Sandberg, Y. Matsuda, M. Jougasaki, and J. C. Burnett Jr. Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1580 - R1585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Schwarz, S. Najam, R. Akel, N. Sulimanjee, S. Bionat, and S. Rosanio Intermittent Outpatient Nesiritide Infusion Reduces Hospital Admissions in Patients With Advanced Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 232 - 236. [Abstract] [PDF]
|
|
|
|
|
|
V. Vats, R. J DiDomenico, J. E Wojtynek, J. C Theobald, and G. T Schumock Hospital Policies for Treatment of Acute Decompensated Heart Failure Ann. Pharmacother., April 1, 2007; 41(4): 562 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L Chow, J. T Peng, M. P Okamoto, and J T. Heywood Effect of Nesiritide Infusion Duration on Renal Function in Acutely Decompensated Heart Failure Patients Ann. Pharmacother., April 1, 2007; 41(4): 556 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Konstam, M. Gheorghiade, J. C. Burnett Jr, L. Grinfeld, A. P. Maggioni, K. Swedberg, J. E. Udelson, F. Zannad, T. Cook, J. Ouyang, et al. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial JAMA, March 28, 2007; 297(12): 1319 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gheorghiade, M. A. Konstam, J. C. Burnett Jr, L. Grinfeld, A. P. Maggioni, K. Swedberg, J. E. Udelson, F. Zannad, T. Cook, J. Ouyang, et al. Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure: The EVEREST Clinical Status Trials JAMA, March 28, 2007; 297(12): 1332 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Forfia, M. Lee, R. S. Tunin, M. Mahmud, H. C. Champion, and D. A. Kass Acute Phosphodiesterase 5 Inhibition Mimics Hemodynamic Effects of B-Type Natriuretic Peptide and Potentiates B-Type Natriuretic Peptide Effects in Failing But Not Normal Canine Heart J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1079 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Kesselheim and M. M. Mello Confidentiality Laws And Secrecy In Medical Research: Improving Public Access To Data On Drug Safety Health Aff., March 1, 2007; 26(2): 483 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Belenkie Nesiritide Administration in Patients With Left Ventricular Dysfunction Undergoing Coronary Artery Bypass Surgery J. Am. Coll. Cardiol., February 13, 2007; 49(6): 727 - 728. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Mentzer Jr, M. C. Oz, R. N. Sladen, A. H. Graeve, R. F. Hebeler Jr, J. M. Luber Jr, N. G. Smedira, and on behalf of the NAPA Investigators Effects of Perioperative Nesiritide in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery: The NAPA Trial J. Am. Coll. Cardiol., February 13, 2007; 49(6): 716 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Kristeller, H. Papps, and R. F. Stahl Risk of worsening renal function with nesiritide following cardiac surgery Am. J. Health Syst. Pharm., December 1, 2006; 63(23): 2351 - 2353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside J. Am. Coll. Cardiol., November 28, 2006; (2006) j.jacc.2006.08.039v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Hauptman, M. A. Schnitzler, J. Swindle, and T. E. Burroughs Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA, October 18, 2006; 296(15): 1877 - 1884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Chen, B. K. Huntley, J. A. Schirger, A. Cataliotti, and J. C. Burnett Jr Maximizing the Renal Cyclic 3'-5'-Guanosine Monophosphate System with Type V Phosphodiesterase Inhibition and Exogenous Natriuretic Peptide: A Novel Strategy to Improve Renal Function in Experimental Overt Heart Failure J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2742 - 2747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Arora Nesiritide: trials and tribulations. Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2006; 11(3): 165 - 169. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Groban and J. Butterworth Perioperative management of chronic heart failure. Anesth. Analg., September 1, 2006; 103(3): 557 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Chen and J. C. Burnett Jr Clinical application of the natriuretic peptides in heart failure Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E18 - E25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Kesselheim, M. A. Fischer, and J. Avorn The rise and fall of Natrecor for congestive heart failure: implications for drug policy. Health Aff., July 1, 2006; 25(4): 1095 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. G. Riter, M. M. Redfield, J. C. Burnett, and H. H. Chen Nonhypotensive Low-Dose Nesiritide Has Differential Renal Effects Compared With Standard-Dose Nesiritide in Patients With Acute Decompensated Heart Failure and Renal Dysfunction J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2334 - 2335. [Full Text] [PDF]
|
|
|
|
|
|
G. L. Smith, J. H. Lichtman, M. B. Bracken, M. G. Shlipak, C. O. Phillips, P. DiCapua, and H. M. Krumholz Renal Impairment and Outcomes in Heart Failure: Systematic Review and Meta-Analysis J. Am. Coll. Cardiol., May 16, 2006; 47(10): 1987 - 1996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Milbrandt, A. Ishizaka, and D. C. Angus Update in critical care 2005. Am. J. Respir. Crit. Care Med., April 15, 2006; 173(8): 833 - 841. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fontana Nesiritide: The Latest Drug for Treating Heart Failure Crit. Care Nurse, February 1, 2006; 26(1): 39 - 47. [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Potter, S. Abbey-Hosch, and D. M. Dickey Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions Endocr. Rev., February 1, 2006; 27(1): 47 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nishikimi, N. Maeda, and H. Matsuoka The role of natriuretic peptides in cardioprotection Cardiovasc Res, February 1, 2006; 69(2): 318 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Hoffman, N. D. Shah, L. C. Vermeulen, G. T. Schumock, P. Grim, R. J. Hunkler, and K. M. Hontz Projecting future drug expenditures--2006 Am. J. Health Syst. Pharm., January 15, 2006; 63(2): 123 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gheorghiade, F. Zannad, G. Sopko, L. Klein, I. L. Pina, M. A. Konstam, B. M. Massie, E. Roland, S. Targum, S. P. Collins, et al. Acute Heart Failure Syndromes: Current State and Framework for Future Research Circulation, December 20, 2005; 112(25): 3958 - 3968. [Full Text] [PDF]
|
|
|
|
|
|
J. B. Bauer and M. A. Randazzo Nesiritide for outpatient treatment of heart failure Am. J. Health Syst. Pharm., December 15, 2005; 62(24): 2639 - 2642. [Full Text] [PDF]
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2125 - 2133. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sackner-Bernstein, K. D. Aaronson, G. Schreiner, P. A. April, and E. J. Topol Nesiritide--not verified. N. Engl. J. Med., October 6, 2005; 353(14): 1525 - 1527. [Full Text] [PDF]
|
|
|
|
|
|
H. M. Krumholz The Year in Epidemiology, Health Services, and Outcomes Research J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1362 - 1370. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Sackner-Bernstein and K. Aaronson Risk of Death With Nesiritide--Reply JAMA, August 24, 2005; 294(8): 898 - 898. [Full Text] [PDF]
|
|
|
|
|
|
Controversies in cardiology Circulation, August 23, 2005; 112(8): iv - iv. [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Deschepper The Many Possible Benefits of Natriuretic Peptides After Myocardial Infarction Hypertension, August 1, 2005; 46(2): 271 - 272. [Full Text] [PDF]
|
|
|
|
|
|
E. J. Topol Nesiritide -- Not Verified N. Engl. J. Med., July 14, 2005; 353(2): 113 - 116. [Full Text] [PDF]
|
|
|
|
 |
|
 Nesiritide Is Associated with Worsening Renal Function Journal Watch Emergency Medicine, May 24, 2005; 2005(524): 1 - 1. [Full Text]
|
|
|
|
 |
|
 Does Nesiritide Increase Risks for Renal Failure and Death? Journal Watch Cardiology, May 6, 2005; 2005(506): 2 - 2. [Full Text]
|
|
|
|
 |
|
 D. Spurgeon Drug for heart failure increases mortality BMJ, April 30, 2005; 330(7498): 981 - 981. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Sackner-Bernstein, M. Kowalski, M. Fox, and K. Aaronson Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials JAMA, April 20, 2005; 293(15): 1900 - 1905. [Abstract] [Full Text] [PDF]
|